The purity of recombinant hM-CSF was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hM-CSF and staining overnight with Coomassie Blue.Learn more about how we get our images
The proliferation of M-NFS-60 cells treated with increasing concentrations of hM-CSF was assessed. After 48 hour treatment with hM-CSF, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.Learn more about how we get our images
Western blot analysis of extracts from M-NFS-60 cells, untreated or treated with hM-CSF for 10 minutes, using Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb #4370 (upper) and p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb #4695 (lower).Learn more about how we get our images
Recombinant human M-CSF (hM-CSF) Glu33-Ser190 (Accession #P09603-3) was expressed in human 293 cells at Cell Signaling Technology.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hM-CSF. All lots are greater than 98% pure.
Recombinant hM-CSF contains no "tags" and the nonglycosylated protein has a calculated MW of 18,403. DTT-reduced protein migrates as a 16-26 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 34-40 kDa protein. Heterogeneity in SDS PAGE is due to glycosylation. The expected amino-terminal EEVSE of recombinant hM-CSF was verified by amino acid sequencing.
The bioactivity of recombinant hM-CSF was determined in a M-NFS-60 cell proliferation assay. The ED50 of each lot is between 0.5-15.0 ng/ml.
Less than 0.01 ng endotoxin/1 μg hM-CSF.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hM-CSF. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
Macrophage-colony stimulating factor (M-CSF) is produced by fibroblasts, endothelial cells, stromal cells, macrophages, osteoblasts and other cell types (1). M-CSF is required for growth and differentiation of monocytes and macrophages (1,2). M-CSF polarizes macrophages into the M2 phenotype where anti-inflammatory IL-10 is produced, rather than the M1 phenotype where inflammatory cytokines are produced. M-CSF also recruits monocytes and enhances angiogenesis by inducing VEGF production (1,2). M-CSF binds to its receptor (CSF1R); downstream signaling involves PI3K/Akt, ERK and STATs 1, 3, and 5 (1,3). An increase in M-CSF expression may contribute to cancer progression and a higher plasma M-CSF level is associated with rheumatoid arthritis (1,4,5).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Explore pathways related to this product.
|8929SC||5 µg (With Carrier)||$ 172|
|8929SF||5 µg (Carrier Free)||$ 172|